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Abstract 
 
Insulin-like growth factor-2 (IGF2) is a key regulator of myogenesis as it promotes 
differentiation of myoblasts during embryonic and fetal development. A single nucleotide 
polymorphism (SNP) identified in pigs in intron 3 of IGF2 disrupts a binding site for the 
transcriptional repressor ZBED6 leading to increased expression of IGF2. The SNP prevents 
binding of ZBED6 increasing IGF2 expression prenatally as well as postnatally compared with 
their wild type counterparts. Pigs with this mutation have a 10 % increase in muscle mass and a 
15% decrease in subcutaneous fat deposition despite similar body weights. Though IGF2 is a 
highly conserved gene across species, similar mutations in IGF2 have not been detected. 
Therefore, the effect of mutations preventing the binding of ZBED6 to IGF2 in species other 
than pigs remains unknown. In order to characterize how a mutation in the ZBED6 binding site 
of IGF2 impacts growth, a mouse model was created using transcription activator-like effector 
nucleases (TALEN) with co-injection of oligo donors. Two founders were generated containing 
mutations that disrupted the ZBED6 binding site. One founder mouse contained the targeted 
G>A point mutation that mimicked the mutation in pigs, and the other founder had an A>G point 
mutation from the designed oligo donor on one allele and a G>A point mutation at the target site 
(A>G/G>A), with the other allele containing a C insertion in the target site (C+). All of these 
mutations inhibited the binding of ZBED6. Founders were bred to wild type (WT) females. The 
offspring produced contained either the C-insertion or A>G/G>A mutations and were bred to 
WT females to create two different mutant lines. Offspring lean and fat mass were evaluated 
through ECHO MRI at 21, 35, 49, 63, and 77 days of age. Offspring were euthanized at 21, 49, 
or 77 days of age and muscle, organ, and fat depot weights were collected. 
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As expected, body weight, fat, and lean mass increased with increasing age (P<0.01). 
Mice with a mutation disrupting ZBED6 binding sites were 10.09-12.73 % heavier than their WT 
counterparts at 49d, 63d and 77d. Additionally, lean mass at 77d of age and fat mass at 45d and 
after were increased (P≤0.05) in mutated mice compared with WT mice as determined by ECHO 
MRI. However, as a percentage of body weight, lean and fat mass did not differ between 
genotypes (P≥0.12). The tibialis anterior was increased (P=0.03) by 20% in mutated mice 
compared with WT mice at 77d, but there were no differences in muscle fiber size and fiber 
cross sectional area (P≥0.64). Liver expression of IGF2 decreased with increasing age in all 
genotypes (P=0.02), and IGF2 expression was increased by 12-32 fold in mutated mice 
compared with their WT counterparts (P≤0.01). In contrast, protein quantification of IGF2 in 
serum of 77d mice did not differ between genotypes (P=0.16). We had hypothesized that mice 
with mutations disrupting the ZBED6 binding site in IGF2 would have increased muscle mass 
and reduced fat deposition at the same body weight, similar to the phenotype of mutant pigs. 
Therefore, the increased mass but apparent lack of altered muscle and fat deposition normalized 
to body weight in mutant mice was unexpected. These results suggest that disrupting ZBED6 
binding in IGF2 affects species differently. It is possible that methylation patterns in tissues 
differ among species, affecting the way ZBED6 interacts with the binding site. This study 
provides insight into how IGF2 influences growth and muscle fiber development, and is the first 
to create a mutation in the ZBED6 binding site in mice.
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Chapter 1 
Literature Review 
 
Introduction 
Insulin-like growth factor-2 (IGF2) is a key regulator of myogenesis as it promotes 
differentiation of myoblasts during embryonic and fetal development. Insulin-like growth factor-
2 expression is elevated before birth and downregulated postnatally (Rotwein and Hall, 1990). 
Mice lacking functional IGF2 experience a nearly 40% reduction in body weights (DeChiara et 
al., 1990; Baker et al., 1993). An increase in IGF2 during embryonic development may result in 
an increase in the number of muscle fibers (Clark et al., 2015). As animals with fewer muscle 
fibers have slower, less efficient lean muscle growth (Dwyer et al., 1993), increasing the number 
of fibers prenatally is of importance to improve efficiency in livestock production.  
A mutation of IGF2 has become virtually fixed in the commercial swine industry and 
causes increased muscle mass and decreased subcutaneous fat deposition in the pigs carrying the 
mutation; thus, it has increased lean meat yield per pig (Van Laere et al., 2003). This mutation is 
a single nucleotide polymorphism (SNP), a G to A substitution, in the transcriptional repressor, 
zinc finger BED-type containing 6 (ZBED6) binding site (Van Laere et al., 2003) within intron 3 
of IGF2. The SNP prevents binding of ZBED6 increasing IGF2 expression prenatally as well as 
postnatally compared to their wild type counterparts (Clark et al., 2015). Though IGF2 is a 
highly conserved gene across species, similar mutations in IGF2 have not been detected in other 
species. Therefore, the effect mutations preventing the binding of ZBED6 to IGF2 in species 
other than pigs remains unknown.  
Insulin-Like Growth Factor Family 
  Insulin-like growth factors (IGF) are a family of hormones that control hyperplasia and 
differentiation throughout the body and, in particular, regulate myogenesis. The IGF family 
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consists of two hormone ligands: insulin-like growth factor-1 (IGF1) and insulin-like growth 
factor-2 (IGF2), and two cell-surface receptors: IGF-Type 1 Receptor (IGF1R) and IGF-Type 2 
receptor (IGF2R) (Liu et al., 1993; Florini et al., 1996). These hormones act in an autocrine, 
paracrine and endocrine fashion. The expression of the two IGF differs in that IGF2 expression is 
increased during embryonic and fetal development and is downregulated after birth, while IGF1 
expression remains elevated postnatally (Rotwein, Pollock, and Watson 1987; Bondy et al., 
1990).  
Insulin-like growth factor binding proteins (IGFBP) are a family of secreted proteins that 
functions as carriers of IGF in circulation, regulate IGF turnover, transport, half-life, and help to 
prevent potential hypoglycemic effects by preventing cross binding of IGF to the insulin receptor 
(IR) (Rajaram, Baylink, and Mohan 1997). These binding proteins bind to IGF1 and IGF2 with 
an affinity equal to or greater than that of IGF1R  (Jones and Clemmons 1995). Six IGFBP exist 
in mammals, numbered 1-6. The majority of circulating IGF is bound in a complex with IGFBP-
3 and an acid-liable subunit, which is thought to extend the half-life of IGF (Guler, Zapf, and 
Froesch 1987; Firth and Baxter 2002). The second most abundant binding protein in circulation 
is IGFBP-2 with the other binding proteins found at lesser concentrations  (Guler, Zapf, and 
Froesch 1987; Firth and Baxter 2002). Insulin-like growth factor binding protein-4 and IGFBP-6 
inhibit the actions of IGF, while IGFBP-1, -2, -3, and -5 both inhibit or enhance IGF activity 
depending on the state of the cell (Yin, Xu, and Duan 2004). Insulin-like growth factor binding 
protein-3 and -5 act independently of IGFs as negative regulators of skeletal muscle growth 
(Baxter 2001). Thus, binding proteins play a large role in the regulation of IGF ligands in 
transport to their receptors.  
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 Insulin-Like Growth Factor-2 
The hormone ligands IGF1 and IGF2 have similar structures to that of insulin. Insulin-
like growth factor-1 and 2 contain an A, B, C and D domain (Figure 1.1). The A and B domains 
are homologous to that of insulin, while the C-domain is cleaved in insulin, and the D domain is 
unique to mature IGF (Roith et al., 2001). The IGF2 gene spans 30 kbp with 9 exons and 4 
promoter regions. Initiating transcription at different start sites, the gene may generate multiple 
transcripts (Rotwein and Hall 1990). This gene is located on chromosome 11 in humans, 7 in 
mice, and 2 in pigs (Glaser et al., 1989; DeChiara et al., 1991; Jeon et al., 1999). Insulin-like 
growth factor-2 is one of several imprinted genes, in which only one allele is expressed. In this 
case, IGF2 is a maternally imprinted gene; therefore, the paternal allele is expressed  (DeChiara 
et al., 1991). Its expression is controlled by the paternally imprinted, maternally expressed H19 
gene located downstream of IGF2 (Bartolomei, Zemel, and Tilghman 1991). The imprinting of 
these genes is controlled by the methylation status of the enhancer region, CTCF (Bell and 
Felsenfeld 2000). When H19 is not expressed, the IGF2 on the paternal allele is expressed. On 
the maternal allele, when H19 is expressed, IGF2 is then repressed. Beckwith-Wiedemann 
syndrome occurs when there are alterations in imprinting in IGF2, H19, or in an imprinting 
control region, and is classified as an overgrowth syndrome. Humans with Beckwith-Wiedemann 
syndrome tend to be larger than their peers, or in some cases may have hemihyperplasia where 
specific body parts larger on one side than the other (Ping et al., 1989; Elliott and Maher 1994). 
However, there is no remains no clear consensus about which regions of the body are affected 
and to what degree of asymmetry is required to make a diagnosis (Tan and Amor 2006).  
Therefore, altered expression of IGF2 can cause distinct phenotypic effects. 
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Insulin-like Growth Factors Receptors  
Insulin-like growth factors act on cells by binding to one of three receptors: the IR, 
IGF1R, or IGF2R (Figure 1.2). There are two isoforms of the IR, IR-A and IR-B, that differ from 
each other by the absence or inclusion of exon 11, respectively. Insulin receptor A has a greater 
expression during gestation than in adulthood and is universally expressed in adult tissues. 
Insulin receptor B is more prevalent in the liver, muscle and adipose tissue of the adult than IR-A 
(Belfiore et al., 2009). The IGF1R is structurally similar with the IR (Meyts and Whittaker 
2002), however, differs from the IR in the binding domains, in the regions that govern ligand 
specificity (Lou et al., 2006). Given the structural similarity between IGF1R and IR, a functional 
heterodimer receptor can form (White et al., 2006). The IR and IGF1R are members of the 
receptor tyrosine kinase (RTK) family however they differ from other members in this family 
due having covalent dimeric (α2β2) structures while the other members of the RTK family 
dimerize on ligand binding (Heldin and Ostman 1996). The IGF2R, also called the mannose-6-
phosphate receptor, is structurally distinct from IGF1R and IR, and is a monomeric 
transmembrane protein with an extracellular domain composed of 15 cysteine-rich repeats 
(Kornfeld 1992). This receptor, like IGF2, is an imprinted gene, however, unlike the IGF2 it is 
maternally expressed (Barlow et al., 1991). The IGF2R has about 100 times greater affinity for 
IGF2 than IGF1 (Kornfeld 1992). Receptor expression is much like that of their ligands; IGF1R 
expression increases postnatally, while IGF2R expression is greatest prenatally (Clark 2015).  
Insulin-like growth factor-2 binds to the IGF1 and IGF2 receptors with different 
affinities. Insulin-like growth factor-2 binds with the greatest affinity to the IGF1R, IGF2R with 
lesser affinity, and the IR with the least affinity with a preference for IR-A. Ligand binding to the 
IGF2R causes the auto-phosphorylation of IGF2R receptor. Receptor/ligand complexes are 
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internalized causing dissociation and degradation in the lysosome system, and inactivation and 
recycling of the receptors (Foti et al., 2004), thus inhibiting downstream signaling (Kornfeld 
1992).  
Insulin-Like Growth Factor Signaling 
Because the IGF2/IGF2R complex becomes degraded by lysosomes, thus inhibiting 
further propagation of signaling, IGF1 and IGF2 signal through the IGF1R. The two major 
pathways induced through IGF1R activation are the Ras/MAP kinase pathway, which is believed 
to elicit proliferation, and the PI3K/ATK pathway which is thought to promote differentiation in 
muscle (Figure 1.3). Activation of the IGF1R through ligand binding causes receptor 
autophosphorylation, which then interacts with intermediate signaling molecules such as Src 
homology containing protein (Shc) and insulin receptor substrate (IRS-1) among others 
(Giorgino and Smith 1995). Signaling through Sch activates the Ras signaling pathway which 
acts through other growth-promoting pathways. This pathway is initiated by the formation of the 
Shc-bound and IRS-1-bound growth factor receptor-bound protein 3 (Grb2) / Son of Sevenless 
(Sos) complexes by Shc or IRS binding to IR/IGFR and recruiting Grb2 (Siddle 2011).  Son of 
Sevenless then activates Ras GDP which leads to the activation of the kinases Raf, MEK, and 
MAP kinase through phosphorylation which recruits transcription factors that ultimately induces 
cell proliferation (Ramos, Langlais, and Hu 2006). 
Insulin receptor substrates (IRS) interact with the phosphotyrosine binding, pleckstrin 
homology, and the tyrosine kinase domains on the IR/IGFR and become phosphorylated when 
IGF1/IGF2 binds to the IGF1R (White 2002; Tseng et al., 2008).  Phosphorylated IRS binds the 
SH2 domain of several proteins including regulatory subunits of PI3K, the Grb2, SHP2 and the 
Fyn (Boura-Halfon and Zick 2009; Sun and Liu 2009). The lipid products of PI3K induce the 
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activation of protein serine kinase cascades by recruiting PDK1 and Akt/PKB (Mora, Komander, 
and van Aalten 2004). The activated Akt/PKB then phosphorylates multiple substrates and 
controls downstream responses such as proliferation, hypertrophy, and differentiation (Manning 
and Cantley 2007).  
IGF Regulation of Muscle and Adipose Tissue Development and Growth 
In skeletal muscle, IGF stimulate myoblast proliferation as well as myogenic 
differentiation (James R Florini et al., 1991; Pirskanen, Kiefer, and Hauschka 2000; Prelle et al., 
2000). In cultured myoblasts, exposure to IGF first causes a proliferative response, then after 36 
hours, an increase in myogenic differentiation occurs (Florini et al., 1996). In differentiating 
muscle cells, IGF stimulate the downstream pathways Akt-mTOR, p38 MAPK, and Erk1/2 
MAPK which promote differentiation and contribute to myogenesis. Postnatally, IGF stimulate 
the MAPK pathway to promote satellite cell activation and proliferation, while the 
PI3K/Akt/mTOR pathway increases protein synthesis and promotes cell survival (Mourkioti et 
al., 2005, Song et al., 2005). 
In adipose tissue, signaling through the IGF1R and insulin receptor increases fat 
deposition and promotes differentiation of preadipocytes into mature adipocytes (Tseng et al., 
2004; Blüher, Kratzsch, and Kiess 2005). Receptor prevalence differs in preadipocytes and 
mature adipocytes with the IGF1R being more prevalent in preadipocytes and the IR 
predominating in adipocytes  (Entingh-Pearsall and Kahn 2004; Bäck and Arnqvist 2009). 
Ligand expression also differs between the two IGF isoforms with IGF2 being more prevalent 
than IGF1 in subcutaneous adipose tissue of pigs (Hausman and Poulos 2006; Gardan et al., 
2008). However, expression of IGF2 declines with adipocyte differentiation in cell culture while 
IGF1 expression does not (Claycombe et al., 2013).  
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IGF Mutations 
Loss of both or either IGF1 and IGF2 results in stunted growth. Mice with a defined 
deletion of paternal IGF2 allele were 60% smaller than those who inherited a mutated maternal 
IGF2 allele (Table 1.1) (DeChiara et al., 1991). Without functional IGF1, mice were 40% 
smaller than their wild type counterparts, and a portion of these mice died within 6 hours after 
birth, while others survived into adulthood (Baker et al., 1993). While the loss of IGF1 or IGF2 
results in a smaller phenotype, overexpression results in a larger phenotype. Overexpression of 
IGF1 in mice increased body weight by 10% and increased lean mass by 13% compared with 
wild type mice (Fiorotto et al., 2003). In pigs, transgenic overexpression of IGF1in skeletal 
muscle increased lean percentage (2% at 60 kg body weight, and 4% at 120 kg body weight), and 
reduced body fat percentage (12% at 60 kg body weight, and 20% at 120 kg body weight) 
(Pursel et al., 2004). Given that mutations of IGF1 and IGF2 result in differing phenotypes, it is 
hypothesized that the two ligands are expressed at differing stages.  
While mutations in IGF ligands can influence growth, mutations in receptors can also 
lead to altered body composition. Mice lacking functional IGF1R experience about a 45% 
reduction in weight compared to that of their wild type littermates and die shortly after birth 
(Baker et al., 1993; Liu et al., 1993). Mouse embryos lacking functional IGF2R exhibited a 25-
30% increase in body weight with an increase in placental growth rate and perinatal lethality 
(Table 1.1). This was accompanied by elevated levels of IGF2 and a corresponding increase in 
insulin-like growth factor binding proteins (IGFBP) (DeChiara et al., 1991; Lau et al., 1994; 
Wylie et al., 2003). Therefore, it is likely that increased signaling through the IGF1R through an 
increase in IGF2 caused an increase in growth.  
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IGF2 Single Nucleotide Polymorphism in Pigs 
A quantitative trait locus is the location on a chromosome where a gene for a quantitative 
trait, a trait that produces a continuous distribution of phenotypes, resides. This can be one or 
several locations as more than one gene may contribute to a quantitative trait. A QTL in IGF2 
that accounted for variability in muscle mass and fat deposition was identified through a whole 
genome scan of crosses between European Wild Boars with Large White domestic pigs and 
Large White and Pietran  (Jeon et al., 1999; Nezer et al., 1999). This QTL explained 10-20% of 
the variation in back fat thickness and 15-30% of the variation in loin eye area between breeds  
(Jeon et al., 1999; Nezer et al., 1999). Van Laere et al., (2003) determined that the QTL was 
caused by G > A single nucleotide polymorphism (SNP) in IGF2-intron3-G3072A. This G>A 
SNP occurred in an evolutionary conserved CpG island that is hypomethylated in skeletal muscle  
(Van Laere et al., 2003).  This SNP is located in a transcriptional repressor binding site, ZBED6, 
in which the mutated A allele prevented ZBED6 from binding, thereby increasing the expression 
of IGF2  (Van Laere et al., 2003; Markljung et al., 2009). In pig skeletal muscle, the CpG island 
located in the binding site was essentially unmethylated with 3.4% methylation, however, the 
liver had an average of 26% methylation (Van Laere et al., 2003). Thus ZBED6 may have a 
greater effect in skeletal muscle than in liver due to its inability to bind methylated binding sites 
(Markljung et al., 2009). The methylation status of the promoter region of IGF2 in other species 
is largely unknown, therefore ZBED6 may have a larger effect in some tissues over others 
depending on methylation status and may differentially impact growth patterns. Due to its 
influence on pork production, selection for meat production in commercial breeds has led to the 
majority of commercial boars having at least one A allele  (Van Laere et al., 2003).  
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There is conflicting data on how this SNP affects birth weight with the majority of 
studies reporting no increase in birth weight in pigs inheriting the A allele from the sire (A 
paternal) compared to those inheriting the G allele (G paternal) (Jeon et al., 1999; Nezer et al., 
1999;  Van den Maagdenberg et al., 2008). Average daily gain was not affected by the SNP, 
however, the paternal A allele caused pigs to have a 0.19 decrease in feed conversion (Van den 
Maagdenberg et al., 2008; Burgos et al., 2011). Pigs carrying the paternal A allele exhibited an 
5% increase in lean yield (Van den Maagdenberg et al., 2008) with a 7% increase in loin eye area 
(Jeon et al., 1999;  Van den Maagdenberg et al., 2008), accompanied by a 7-21% reduction in 
back fat thickness (Jeon et al., 1999; Jungerius et al. 2004; Gardan et al., 2006; Van den 
Maagdenberg et al., 2008; Burgos et al., 2011). Clark et al., (2015) reported a 0.41 cm decrease 
in back fat thickness and a 4 cm2 increase in loin eye area, at the same ending live weight 
between A paternal pigs and G paternal pigs.  
Despite increased muscle accretion often being associated with decreased meat quality (a 
prediction of the final eating quality of meat using measures such as color, moisture, pH, and 
firmness), there were no differences in drip loss, cook loss, and ultimate pH between G paternal 
and A paternal pigs (Dransfield and Sosnicki 1999; Burgos et al., 2011; Van den Maagdenberg et 
al., 2008). Instrumental tenderness (WBSF) was not affected by genotype (Van den 
Maagdenberg et al., 2008; Clark et al., 2014). An increase in L* values (lightness) of the 
longissimus dorsi was reported in A paternal pigs compared with G paternal, however the 
difference between A paternal pigs compared with G paternal was only a 1.12- 2.36 unit 
difference and therefore not likely to impact consumer perception (Burgos et al., 2011; Clark et 
al., 2014). Belly quality characteristics were reduced in A paternal pigs with a 7.17 mm decrease 
in thickness, 7.27 cm decrease in flop distance and 1.34 units greater iodine value compared with 
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G paternal pigs (Clark et al., 2014). It has been previously reported that thinner bellies with a 
greater amount of saturated fatty acids are more difficult to slice (Seman et al., 2013). Bacon 
slice moisture percentage from A paternal pigs had 4.73 percentage units greater (P<0.01) but 
had 6.67 percentage units less fat than compared with G paternal pigs (Clark et al., 2014). Bacon 
consumer sensory attributes from thin (47.9% fat and 36.2% moisture) and average (47.9% 
moisture and 36.2% fat) bellies were greater than bacon from thick bellies (40.4% moisture and 
46% fat) (Person et al., 2005), therefore bellies from A paternal pigs would likely have similar 
sensory attributes to G paternal pigs and would not affect consumer preference. Overall, pigs 
with an A paternal allele had a greater amount of lean yield with minimal effects on fresh meat 
quality and belly quality.   
Due to the IGF2 mutation’s location in the ZBED6 transcriptional repressor binding site, 
an increase in IGF2 expression occurs. While previously reported that expression during prenatal 
development was not different between genotypes  (Van Laere et al., 2003), Clark et al. (2015) 
suggested that IGF2 expression is increased 1.5 fold as early as 90 days of gestation in A 
paternal pigs, and remain elevated throughout gestation. This increased expression at birth may 
have contributed to the increased number of muscle fibers observed on postnatal day 176. Not 
only did the A paternal pigs have increased prenatal IGF2, IGF2 expression was increased 
postnatally. The expression of IGF2 decreases with age. While all genotypes had decreased IGF2 
expression with age, pigs that expressed the paternal A allele had 2.7-4.5 fold greater expression 
of IGF2 at postnatal day 21 and 176 compared to wild types (Clark et al., 2015). Because of 
IGF2’s role in myogenesis, this increase in prenatal expression may increase muscle fiber 
number, which increases the growth potential of an animal (Dwyer and Fletcher 1993).  
 
	
	
11	
ZBED6 
 The ZBED6 gene belongs to the hAT transposase family, contains two amino-terminal 
zinc finger BED domains (Andersson et al., 2010), and is an intronless alternate splice variant of 
the Zc3h11a gene (Markljung 2009). This family contains active DNA transposons in many 
species. The location of ZBED6 in the genome, as well as the DNA binding domain, is highly 
conserved among species. The expression of ZBED6 is dependent on the presence of the ZBED6 
sequence remaining in the transcript. If the intron containing ZBED6 is spliced out, ZC3H11A is 
translated (Andersson et al., 2010). The ZBED6 gene is widely expressed during development 
and in adult tissues in mice (Markljung 2009). It is localized in the nucleus of the cell where it 
can modulate transcription. The ZBED6 protein represses transcription of IGF2 in the P3 
promoter. When ZBED6 is silenced, there is an increase in IGF2 expression and cell 
proliferation with stimulated myotube formation. The ZBED6 protein preferentially binds 
proximal promoters rather than distal enhancers and is strongly associated with CpG islands  
(Markljung et al., 2009). A gene ontology study demonstrated that of the approximately 1,200 
genes associated with a ZBED6 binding site, as many as 22% of them were associated with 
development, regulation of biological processes and regulation of transcription (Andersson et al., 
2010). This indicates that ZBED6 may influence growth and development by altering many 
signaling pathways, however, it is not fully understood the extent of its regulation. Silencing of 
ZBED6 in C2C12 cells caused a 2.5-fold increase in IGF2 mRNA expression however it is 
unknown how ZBED6 silencing can affect IGF2 expression and muscle growth in vivo  
(Markljung et al., 2009). Genome editing technology can be utilized to study how ZBED6 
influences IGF2 expression and muscle growth in vivo through silencing of the gene or by 
modifying its ability to bind to its targets.  
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Genome Editing Technology 
Animal models, especially mice, have been created to better understand the function of 
genes and disease by introducing mutations into the genome by causing double-stranded breaks 
using genome editing tools. Technologies used to generate transgenic organisms include zinc 
finger nucleases (ZFN), clustered regularly interspaced short palindromic repeats/CRISPR-
associated (CRISPR/Cas), and transcription activator-like effector nucleases (TALEN). These 
technologies are characterized by a sequence recognition system with a nonspecific 
endonuclease, which cleaves double-stranded DNA. Using sequence-specific DNA-binding 
proteins or RNA sequences, endonucleases can be directed to specific targets in the genome. 
Gene modifications, such as gene disruption, correction, or insertion, may occur after the 
endonuclease activates DNA repair machinery through double-stranded breaks (DSB). While 
nuclease driven modifications are a powerful tool for creating transgenic animals, they may have 
undesired consequences associated with them such as off target cleavages, especially in the 
CRISPR system. Transcription activator-like effector nucleases have been suggested to be a less 
cytotoxic, more specific, and a faster approach than ZFN (Mussolino, Morbitzer et al., 2011; 
Osiak, Radecke et al., 2011). 
Transcription Activator-Like Effector Nuclease 
Transcription activator-like effectors (TALE) were originally discovered in the plant 
pathogen Xanthomonas bacteria. Transcription activator-like effectors are used to manipulate 
plant eukaryotic pathways to reprogram host cells by mimicking eukaryotic transcription factors 
and binding to promoter regions during pathogenesis  (Büttner and Bonas 2010). The TALE 
mediated changes in gene expression can induce cell division and enlargement causing disease 
symptoms in the plant  (Kay et al., 2007). These changes in transcription occur when the TALE 
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is imported into the plant cell nucleus and targeted to effector-specific gene promoters which 
then bind to elicit expression of downstream genes (Bogdanove et al., 2011). The functionality of 
the DNA recognition of the TALE can be exploited for DNA targeting in vivo.  
Transcription activator-like effector nucleases (TALEN) contain conserved N-terminal 
and C-terminal regions and a central region with tandem repeats of 34 amino acid residues. 
These tandem repeats are highly conserved with the exception of the 12th and 13th position which 
are hypervariable and named repeat variable di-residues (RVD) (Boch and Bonas 2010). The two 
amino acid repeat at the 12th and 13th position correlate with specific base pairs of DNA and 
determine sequence specificity, by which one repeat corresponds to a single base pair and the 
tandem array of repeats corresponds to a sequence of DNA. The amino acid repeat histidine and 
aspartic acid (HD) has a strong preference for binding to the nucleotide cytosine, repeat 
asparagine and isoleucine (NI) has a strong affinity for adenine, asparagine and glycine (NG) to 
thymine, asparagine and asparagine (NN) will recognize adenine and guanine with a preference 
for guanine, while asparagine and serine (NS) does not have a preference for a nucleotide  (Boch 
et al., 2009). These RVD create a one-to-one binding of protein to DNA interaction so that one 
RVD in a tandem repeat codes for 1 nucleotide (Figure 1.4). In order for promoter activation, a 
thymine is needed at position 0 of the target DNA sequence  (Boch et al., 2009). While TALEN 
do allow for specific binding to a target DNA sequence, it is limited to sites that are 
unmethylated. If a target site contains a methylated CpG site, the TALE will not be able to bind 
effectively (Bultmann 2012; Kim 2013).     
Double-stranded breaks in the target DNA strand can be accomplished by combining the 
TALE with FokI, a restriction endonuclease that contains a DNA recognition domain and a 
catalytic domain that functions as a dimer to cleave double-stranded DNA (Bitinaite et al., 1998). 
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Because FokI is only active as a dimer (Bitinaite et al., 1998), TALEN is designed as active pairs 
in which two monomers bind a sequence adjacent to the target DNA. A 12–20 base pair spacer 
allows for the formation of the active FokI dimer to cleave at the target locus (Sung et al., 2014).  
This double stranded break causes the DNA to be repaired by either non-homologous end joining 
or homologous recombination. Homologous recombination uses sequence homology to align and 
join the two broken strands of DNA. Non-homologous end joining causes the two strands of 
DNA to be joined in the absence of sequence homology and is prone to errors such as insertions, 
deletions and substitutions (Szostak et al., 1983). 
Several successful studies have utilized single-strand oligodeoxynucleotides (ssODN) as 
a template for specific mutations after a double stranded break has been induced by TALEN  
(Panda et al., 2013). By co-injecting a ssODN with the TALEN, a template is provided for the 
DNA repair mechanism to use, and can be designed with a desired mutation that can be 
incorporated into the newly repaired DNA strand. Injecting a TALEN ssODN mixture directly 
into the nucleus of the single cell embryo had a greater success rate for incorporation as opposed 
to the cytoplasm, especially when inducing targeted mutations (Panda et al., 2013). The 
pronuclear injection ensures that the targeting molecule and the TALEN is delivered directly to 
the genomic DNA and are able to provide a template for repair after homologous recombination.  
Transcription activator-like effector nucleases are assembled using several different 
methods including a “Golden Gate” cloning system, solid-phase assembly, fast ligation-based 
automatable solid-phase high-throughput (FLASH) system, iterative capped assembly, or 
ligation-independent cloning methods.  Single step Golden-Gate cloning employs a total of 424 
TALE array plasmids and 8 obligatory heterodimeric FokI-encoding plasmids. The TALE array 
plasmids are divided into six subgroups according to their positions. Each array in a given 
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position generates the same four-base overhang sequence when digested with BsaI. Transcription 
activator-like effector nucleases arrays in different positions produce different four-base 
overhang sequences. One member in each of the six positions is chosen; the six arrays are 
combined with each other for subcloning into one of the FokI expression plasmids. This system 
allows construction of TALEN plasmids that contain at least 14.5 and up to 18.5 RVD modules 
in a single Golden-Gate reaction. The last half-repeat is encoded in the FokI plasmids  (Kim et 
al., 2013). Using this method, TALEN can be generated to target specific sequences and cause 
mutations that allow for the study of that gene.  
Objectives 
 The IGF2-intron3-G3072A mutation in pigs resulted in increased IGF2 expression and 
increased muscle mass. In order to better to characterize this mutation and its effects on muscle 
growth, our first objective was to create a transgenic mouse model for the IGF2 mutation using 
TALEN to disrupt the ZBED6 binding site. The mouse model allows for the study of the 
mutation in a controlled environment with little genetic variation between animals and a faster 
generation rate.  
The second objective was to characterize the body composition, muscle fiber number and 
muscle fiber size in mice with mutated paternal alleles; as well as the effects on the expression of 
IGF2. The hypothesis was that the mutation will inhibit ZBED6 from binding, thus increasing 
the expression of IGF2 postnatally. As reviewed, increased IGF2 in pigs caused increased 
muscle mass and decreased subcutaneous fat deposition. Due to the conserved homology of 
IGF2 among species, we would expect this mutation in mice to have the same outcome. By 
characterizing the IGF2-intron3-G3072A mutation through a transgenic mouse model in this 
study, we will gain a better understanding of how IGF2 influences growth.  
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Tables 
Table 1.1 Resulting Phenotypes of Mutations in IGF Family Members and their Receptors 
Genotype 
Weight Percentage 
of Wild Types Lethality References 
Lacking IGF1 40% Die shortly after birth Baker et al., 1993 
Lacking IGF1R 45% Die at birth Liu et al., 1993 
Lacking IGF2 60% Non-lethal DeChiara et al., 1990 
Lacking IGF2R 135% Perinatally lethal Ludwig et al., 1996 
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Figures 
 
 
 
Figure 1.1 (A) Structure of IGF-II preprohormone (adapted from O’Dell et. al 1998).  (B) 
Structural organization of the prepropeptides of the Insulin-like Growth Factor (IGF) family with 
the A, B, C, D, and E domains indicated (adapted from Nielsen 1992). 
  
B A 
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Figure 1.2 Overview of the insulin and insulin-like growth factor family system, illustrating the 
affinities of the ligands to the receptors. (Chao and D’Amore, 2008)  
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Figure 1.3 Canonical signaling pathways and principle components of the PI3K/Akt and 
Ras/MAP kinase pathways. Receptors are indicated in red, tyrosine phosphorylated in substrates 
shown in orange, adaptors and transducers in yellow/gray, serine/threonine kinases in green, 
downstream components in blue and negative regulators shown in purple (Adapted from Siddle 
2011).   
	
	
20	
 
Figure 1.4 A schematic representation of a TALEN pair with a FokI domain. Each TALE repeat 
is composed of 33-35 amino acids with position 12 and 13 being the RDV (shown in red) that 
binds to a specific nucleotide (Kim and Kim 2014). 
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Chapter 2 
 
CREATION AND CHARACTERIZATION OF MICE WITH A MUTATION 
DISRUPTING BINDING OF A TRANSCRIPTIONAL REPRESSOR OF IGF2 
INTRON3-G3072A 
 
Abstract 
An intronic region of insulin-like growth factor-2 (IGF2) contains a binding site for the 
transcriptional repressor zinc finger, BED-type containing 6 (ZBED6). A G>A single nucleotide 
polymorphism located in this binding site leads to increased expression of IGF2 in pigs. Pigs that 
inherited a paternal copy of this mutation had a 10% increase in muscle mass and a 15% 
decrease subcutaneous fat deposition compared with pigs without the mutation at similar body 
weights. To determine the effect of preventing ZBED6 binding to IGF2 on muscle development 
and growth in species other than the pig, a mouse model was created with disruptions in the 
ZBED6 binding site of IGF2. Transcription activator-like effector nucleases (TALEN) were used 
to target double-stranded DNA breaks in the ZBED6 binding site. Two founder male mice were 
created containing three mutated alleles: the targeted G>A point mutation (G>A); the targeted 
G>A point mutation plus an additional designed A>G substitution (A>G/G>A); and, a C 
insertion in the target site (C+). Male mice heterozygous for either the A>G/G>A or C+ mutation 
were bred to wild type female mice to produce offspring with paternally inherited mutant or wild 
type (WT) alleles. Male offspring lean and fat mass were evaluated with ECHO MRI, and at 
least 8 offspring of each genotype were euthanized at 21, 49, 77d of age. Muscle, organ, and fat 
depot weights were collected. As expected, body weight, lean, and fat mass increased with 
increasing age (P<0.01) regardless of genotype. Mice with either the paternally-inherited 
A>G/G>A or C+ mutation were 10-13% heavier (P£0.05) than WT mice at 49d, 63, and 77 of 
age. Accordingly, at 49, 63, and 77d of age, mutated mice had 17-36% more fat mass than WT 
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mice (P≤0.05). Mutated mice had 12% more lean mass (P=0.02) than their WT counterparts at 
77d. However, as a percentage of body weight, lean and fat mass did not differ between 
genotypes (P≥0.12) with the exception of fat at 49d which A>G/G>A had 28% greater (P=0.02) 
fat than C+ and WT mice. The absolute weight of the tibialis anterior (TA) was increased by 
20% in mutated mice compared with wild type mice at 77d (P=0.03). However, there were no 
differences among genotypes in muscle fiber size and fiber cross sectional area (P≥0.64) of the 
TA in 77d old mice. The expression of IGF2 in the liver decreased with increasing age in 
mutated mice (P=0.02) but was increased by 12-32 fold in mutated mice compared with their 
WT counterparts (P≤0.01). However, protein quantification of IGF2 in serum from 77d old mice 
resulted in no differences among genotypes (P=0.16). In this study, we successfully created mice 
with a mutation in the ZBED6 binding site of IGF2 that disrupted ZBED6 binding and increased 
IGF2 expression in the liver, which may have contributed to their increased body weights. 
However, unlike pigs with similar mutations in IGF2, dramatically increased muscle growth was 
not apparent. Overall, these preliminary data suggest that the phenotype of mice with mutations 
disrupting the ZBED6 binding site in intron 3 of IGF2 differs from that of pigs.  
Introduction 
Insulin-like growth factors (IGF) are hormones important in the control of hyperplasia 
and differentiation of muscle (Engert et al., 1996). Insulin-like growth factor-2 (IGF2) is thought 
to be primarily responsible for prenatal growth, and IGF1 is involved in both prenatal and 
postnatal growth (Lui et al., 1993; Rotwein et al., 1987). Both act through the insulin or IGF1 
receptor (LeRoith et al., 1995). The expression of IGF2 was elevated prenatally and decreased 
after birth in mice (DeChiara et al., 1990, 1991) while the expression of IGF1 remained elevated 
postnatally (Lui et al., 1993; 2008; Baker et al., 1993). Due to its relatively low expression 
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compared with IGF1 postnatally, effects of IGF2 on postnatal muscle growth are not well 
characterized.  
However, in pigs, the G>A single nucleotide polymorphism (SNP) in intron 3 of IGF2 
prevents the binding of a transcriptional repressor, increasing the expression of IGF2 (Markljung 
et al., 2009). This transcriptional repressor, zinc finger BED-type containing 6 (ZBED6), is 
localized in the nucleus of the cell where it can modulate transcription of unmethylated DNA. 
The ZBED6 gene is widely expressed during myogenesis and development, and in adult tissues 
in mice, with the highest expression in skeletal muscle (Markljung et al., 2009). When ZBED6 is 
silenced, IGF2 expression increased resulting in increased myoblast proliferation and myotube 
formation in culture (Markljung et al., 2009). Prevention of ZBED6 binding, in turn, increases 
the expression of IGF2 (Van Laere et al., 2003). Pigs with a paternally mutated allele had 
increased expression of IGF2 prenatally in muscle and maintained elevated expression 
postnatally (Clark et al., 2015). Pigs carrying a paternally inherited mutation exhibited a 10% 
increase in longissimus area (Jeon et al., 1999; Van den Maagdenberg et al., 2008), accompanied 
by a 7-21% reduction in back fat thickness, a measure of fat deposition (Jeon et al., 1999; 
Jungerius et al., 2004; Gardan et al., 2006; Van Den Maagdenberg et al., 2007; Burgos et al., 
2011). This suggests that IGF2 is important in regulating prenatal as well as postnatal muscle 
growth, and increased expression of IGF2 postnatally can increase muscle mass.  
The IGF2 intron3-G3072A mutation is unique to pigs, and no other mutation that results 
in increased IGF2 expression has been discovered in livestock species. Due to the mutation 
residing in a CpG island that is highly conserved across species (Amarger et al., 2002; Van 
Laeere et al., 2003), it is hypothesized that increasing IGF2 expression through disruption of the 
ZBED6 binding site would have similar effects in other species as observed in pigs.  
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The advent of genome-editing technologies like transcription activator-like effector 
nucleases (TALEN) that can generate site-specific double-stranded DNA breaks using a FokI 
domain have allowed for the generation of specific mutations (Bitinaite et al., 1998). Double-
stranded DNA breaks can be repaired by nonhomologous end-joining, which is error-prone and 
often leads to mutations such as deletions and substitutions (Szostak et al., 1983). When these 
deletions or mutations occur in critical gene regions, they often cause altered function of 
resulting proteins or can silence the gene. Double-stranded DNA breaks can also be repaired 
through homologous recombination, and mutations can be introduced by providing an 
oligodeoxynucleotide as a mutated template (Panda et al., 2013). Thus, our objectives were to 
create mice with a mutation identical to the IGF2 mutation in pigs using TALEN with 
oligodeoxynucleotide donors and characterize the resulting phenotype.  
Materials and Methods 
 
All animal procedures were approved by the University of Illinois Institutional Animal Care and 
Use Committee. 
 
TALEN Target Site Design and Founder Generation 
The mouse IGF2 gene (GenBank accession number: U71085.1) was scanned for potential 
TALE target sites using ZiFiT Targeter Version 4.2 (Sander et al., 2007; Sander et al., 2010). 
The target site for the double-strand break was nucleotide 14195 (Table 2.1). For effective use of 
TALEN, the target site and surrounding sequence must be free of methylated CpG sites. To 
determine the methylation status of the IGF2 intron 3 14195 locus and the surrounding CpG 
sites, mouse embryonic stem cell DNA from CJ7 cells were analyzed with bisulfite treatment 
using the EZ DNA Methylation™ Kit (Catalog Nos. D5001 and D5002 Zymo Research, CA). 
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Methylation products were then subjected to bacterial artificial chromosome cloning with 
TOPO® TA Cloning® Kit for Sequencing, with One Shot® TOP10 Chemically Competent E. 
coli (Thermo Fisher Scientific Inc; Waltham, MA) following manufacturer’s protocols to clone 
and isolate IGF2 products for sequencing. Sanger Sequencing was performed by the Roy J. 
Carver Biotechnology Center (Urbana, IL). Bisulfite sequences were aligned using CodonCode 
Aligner (www.codoncode.com) and methylation analysis was performed using Quantification 
tool for Methylation Analysis (QUMA, RIKEN Center for Developmental Biology) using a 
reference sequence of accession number U71085.1 with location 74 representing the IGF2 G>A 
mutation site. Sites 29 to 127 were in the TALEN binding regions. Methylation was not observed 
that would affect TALEN binding (Figure 2.1), therefore the use of TALEN to induce the 
mutations in the ZBED6 binding site would be possible.  
Oligodeoxynucleotides were designed with the G>A point mutation to allow for 
homology directed repair plus an additional two mutations in each TALEN binding site to 
prevent re-binding (Table 2.2). Cyagen Biosciences (Santa Clara, CA) constructed the TALEN 
using the Golden Gate Assembly method, and confirmed the TALEN sequence through 
sequencing. Transcription activator-like effector nuclease mRNA was generated by in vitro 
transcription, and was then injected into fertilized C57BL/6J mouse eggs with the oligo donor for 
knock-in mouse production. Founders were genotyped by PCR followed by DNA sequencing 
analysis.  
Founders were mated with wild type C57BL/6 females to generate F1 generation mice. 
One F1 male was produced from the founder with one G>A mutant allele. Four F1 mice were 
generated from the founder with two mutates alleles (A>G/G>A and C+); one female and two 
males containing the C+ mutation, and one male with mutation G>A. These five F1 mice were 
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shipped to the University of Illinois and then bred to wild type C57BL/6J mice to expand the 
population of mice with mutant alleles. 
Animals and Sample Collection 
 After colony expansion, male mice containing a paternal mutant allele were bred to 
C57BL/6J wild type females (Jackson Laboratory; Bar Harbor, ME) in harem breeding pairs 
containing 2-3 females for one week before separation. After separation, females were 
individually housed until offspring were weaned. Mice were provided free access to a Teklad 
chow diet (Harlan; Indianapolis, IN) and water, were maintained in a 12-hour light/dark cycle, 
and were group housed after weaning. Offspring were genotyped, and three genotypes of male 
mice were used for this experiment. Genotypes included mice with no mutated IGF2 alleles 
(wild type, WT), those with paternally-derived A>G/G>A substitution (A>G/G>A), and those 
with paternally derived C-insertion (C+).  
 For the longitudinal analysis of body weight and composition, 8 male mice of each 
genotype were used. These mice represented 11 litters and were randomly chosen for analysis 
without accounting for litter of origin. At 21 ± 1d, 35 ±3d, 49 ±3d, 63 ±3d, and 77 ±3d of age, 
mice were weighed and body composition was analyzed with ECHO MRI (EchoMRI™, 
Houston, TX). Lean and fat as a percentage of body weight were calculated by dividing the lean 
or fat mass by body weight.  
 To determine muscle, fat pad, and organs weights, 8 male mice from each genotype were 
also allotted to two additional groups for sacrifice at 21 ± 1d and 49 ±3d. Along with the 77d old 
mice, they were euthanized by asphyxiation with carbon dioxide followed by cervical 
dislocation. For the mice aged 21d, 11 litters were represented while at 49d of age, 9 litters were 
represented. Mice were assigned to groups without respect to litter of origin.  
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Mice were weighed prior to euthanasia to obtain an ending live weight (ELW), and blood 
was then obtained by cardiac puncture. Carcass weight was determined after the removal of skin, 
head, feet, tail and internal organs. Weights were obtained from liver, and samples were stored at 
-80°C for further analysis.  The following muscles were collected from both sides of the carcass, 
weighed, and the average weight of the two sides calculated: triceps brachii (TB), biceps femoris 
(BF), gastrocnemius and soleus complex (G), and tibialis anterior (TA). The left TA was 
embedded in Optimum Cutting Temperature Compound (O.C.T.) (Sakura® Finetek; Torrance, 
CA) and snap frozen in isopentane cooled with liquid nitrogen. The subscapular fat pads (SF), 
inguinal fat pads (IF), epididymal fat pad (EF), and retroperitoneal fat pads (RF) were removed 
and weighed. Tissue weights were also expressed as a percentage ending live weight.  
Genotyping 
Isolation of DNA from tail snips was performed with the DNA Prep for PCR Extracta Kit 
(Quanta Biosciences; Gaithersburg, MD) according to manufacturer instructions. Genotyping 
was accomplished by the HotStarTaq® Plus DNA Polymerase kit (Qiagen; Hilden, Germany) 
with custom IGF2 primers (Table 2.3). Thermocycler parameters were as follows: 95°C for 5 
min followed by 40 cycles of 94°C for 45 s, 62°C for 45 s, 72°C for 1 min and PCR products 
were digested with Cac8I or StuI (New England BioLabs Inc; Ipswich, MA) for the G>A and C+ 
mutations, respectively. Products were visualized on a 1.6% agarose gel. For the G>A mutation, 
the mutated allele digested with Cac8I resulted in bands of 335 and 87 bp while wild type allele 
had band sizes of 237, 87, and 82 bp. The C+ mutant allele digested with StuI resulted in band 
sizes of 271 bp and 172 bp, while the wild type alleles would not be digested giving a band size 
of 443bp (Figure 2.2).  
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Electrophoretic Mobility Shift Assays 
Nuclear protein was extracted from skeletal muscle tissue of wild type C57BL/6J mice 
using the EpiQuik™ Nuclear Extraction Kit (EpiGentek; Farmingdale, NY) following 
manufacturer’s protocol. Extracted protein was quantified using the BCA protein Assay Kit 
(Pierce, Rockford, IL). Oligodeoxynucleotides were designed for each of the mutations of IGF2 
(Thermo Fisher Scientific Inc; Waltham, MA) (Table 2.4). Supershift of protein-DNA complexes 
was accomplished using a ZBED6 antibody in a 1:20 dilution (Santa Cruz Biotechnology Inc.; 
Dallas, Texas). Binding of the 300 µM oligodeoxynucleotide and 60,000 µg/ml of protein was 
allowed to proceed for 30 minutes in solution on ice. DNA-protein complexes were resolved on a 
6% native polyacrylamide gel in 0.5x TBE running buffer at 24 °C for 3 hours at 125V. The gel 
was visualized using the Electrophoretic Mobility-Shift Assay (EMSA) Kit, with SYBR® Green 
and SYPRO® Ruby EMSA stains (Thermo Fisher Scientific Inc; Waltham, MA) according to 
manufacturer’s instructions. 
RNA Isolation and cDNA Preparation 
From liver samples, RNA was isolated and quantified as described by Jones et al., (2014) 
and then was further purified using an RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA 
integrity was examined by electrophoresis on a 1.2% formaldehyde denaturing gel. Synthesis of 
cDNA was completed with according to manufacturer’s instructions in which 1µg of RNA was 
added to qScript cDNA SuperMix (Quanta Biosciences, Gaithersburg, MD) and incubated at 25° 
C for 5 minutes, 42° C for 30 minutes, and 85° C for 5 minutes and stored at -20° C.  
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Quantitative Polymerase Chain Reaction  
Quantitative polymerase chain reaction (qPCR) was completed with PerfeCTa FastMix II 
ROX (Quanta Biosciences, Gaithersburg, MD) in accordance with manufacturer’s directions 
using a 1:100 cDNA dilution. Expression of 18S rRNA and actin were unaffected by genotype 
and age, and had an efficiency between 90 and 100%, therefore were acceptable endogenous 
controls. On a 96 well plate, reactions were performed in triplicate comparing IGF2 expression 
with two endogenous controls. Primer probes were obtained from Thermo Fisher Scientific Inc. 
(Waltham, MA) (Table 2.5). Gene expression was determined using a Step One qPCR machine 
with the following thermocycler procedure: 50º C for 2 min, 95º C for 10 min followed by 40 
cycles of 95º C for 15 s, 60º C for 1 min. The ΔΔCT method was used to calculate fold change 
between genotypes and age combinations. The gene of interest was normalized to the average Ct 
for both endogenous controls and expressed as a fold change compared to 35d WT mice.   
Serum IGF2 Protein Quantification 
 Blood was collected through cardiac puncture immediately after CO2 asphyxiation and 
cervical dislocation. Blood was allowed to clot at room temperature for at least 15 minutes, and 
serum was separated by centrifugation at 15,000×g for 15 minutes. Protein concentrations for 
IGF2 were determined on a 1:50 dilution of protein extract solution using PierceTM BCA 
Protein Assay Kit (Thermo Scientific, Waltham, MA) following manufacturer procedures. 
Protein concentrations were standardized to 5µg/ml. Following manufacturer recommendations, 
serum samples were diluted 1:10 so that samples were to fall in the middle of the standard curve, 
and quantified by a Mouse IGF2 ELISA kit (EK0381, Boster Biological Technology Co., Ltd., 
Fremont, CA) with a sensitivity of < 5pg/ml and no detectable cross-reactivity with IGF1. 
Absorbance was measured at 450nm with a plate-reader spectrophotometer (Synergy HT; 
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BioTek, Winooski, VT). Samples were measured in duplicate and compared to a standard curve 
ranging from 4,000 pg/mL to 0 pg/mL.   
Muscle cell number and size 
 To determine muscle cell number and cross-sectional area, TA muscles from carcasses of 
77d old mice were used. Frozen cross-sections (10µm thick, 4 per mouse) were obtained using a 
Lecia CM 1850 Cryostat (Lecia Biosystems; Buffalo Grove, IL). Slides underwent hematoxylin 
and eosin (H&E) staining, and images were captured using an AMG Exos XL Microscope 
(EVOS, Bothell, WA) under both 40× and 4× magnification. Whole muscle cross-sectional area 
(CSA) and muscle fiber CSA were measured using Adobe Photoshop (Adobe Systems 
Incorporated, San Jose, CA). For whole muscle, one pixel was equal to 0.447 µm while for 
muscle cells one pixel was equal to 4.4 µm. A minimum of 200 cells per mouse were analyzed. 
Total fiber number within the TA was estimated by dividing the CSA of the TA by the average 
muscle fiber CSA.  
Statistical Analysis 
Data were analyzed using the Mixed procedure in SAS version 9.3 (SAS Institute Inc., 
Cary, NC), and individual mouse was the experimental unit for all traits measured. Data were 
analyzed as a randomized complete design in a factorial arrangement of treatments. To compare 
genotypes within each age, data were analyzed as a one-way ANOVA. The effects of genotype 
on muscle cell size and number and IGF2 protein concentrations were analyzed as a one-way 
ANOVA.  For the longitudinal analysis of body weight and composition, data were analyzed as 3 
× 5 factorial with repeated measures with mouse serving as the repeated unit with genotype and 
age as the main effects, and a Tukey adjustment was used to protect against type 1 error due to 
multiple comparisons. Least square means were separated with the PDIFF option. Statistical 
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differences were accepted as significant at P<0.05, and trends were noted at 0.05<P<0.10. Due 
to computer failure at time of dissection, data was lost for one WT mouse at 49d for all muscle, 
fat, and carcass weights. Observations two standard deviations away from the mean within each 
age or greater were removed. This resulted in one WT observation being removed for IF, IF as a 
percentage of ELW, SF as a percentage of ELW, and EF as a percentage of ELW at 77d. 
Additionally, for RF and RF as a percentage of ELW, two C+ mice were removed and one WT 
mouse was removed at 21d, and at 77d one A>G/G>A mouse was removed. 
 Results  
Creation of mice with mutations that prevent ZBED6 binding site to IGF2 
Methylation occurs most often in promoter regions which are rich in CpG islands 
(Ehrlich et al., 1982). The targeted site for the mutation of the ZBED6 binding site is located in 
the intron 3 of IGF2 which contains a promoter region as well as CpG islands (Van Laere et al., 
2003). Bisulfite sequencing of CJ7 cells allowed us to determine if the use of TALEN would be 
possible to induce the mutations at the single cell stage since TALEN are sensitive to 
methylation which inhibits binding to the DNA sequence. The TALEN binding sites included 17 
CpG islands, locations 29-127 (Figure 2.1).  The targeted site for mutation, location 74, 
contained no methylation allowing for the FolkI domain of the TALEN to be able to make a 
double stranded break at that site. The TALEN binding sites on either side of the spacer region 
contained only 4 CpG islands each with 10% methylation. The remaining CpG islands did not 
contain any methylation. Due to the low frequency of methylation in the binding sites, it was 
anticipated that there would be no interference of TALEN binding at this stage of development. 
Pre-implantation embryos undergo a series of demethylation steps that reprogram the embryo to 
a pluripotent state (Mayer et al., 2000). By the time the embryo develops into a blastocyst, 
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methylation levels are at their lowest. After implantation, remethylation patterning begins as 
cells begin to differentiate (Santos et al., 2002). Therefore, despite a lack of methylation in the 
ZBED6 binding site in the embryo, tissues in the mouse may be methylated at this site.  
Injection of TALEN and oligodeoxynucleotides into fertilized eggs resulted in the 
production of two male mice with mutations in the target site of IGF2. The first mouse had the 
targeted G>A point mutation on one allele. The second mouse had mutations in both alleles. One 
allele had a G>A point mutation at the target site with an additional A>G point mutation located 
at nucleotide 14180 resulting from incorporation of the designed oligo template. The other allele 
contained a C insertion in the target site (C+) (Figure 2.3).  
 Given the location of these mutations in the predicted binding site of ZBED6, these 
mutations were expected to preclude ZBED6 binding to IGF2. Therefore, oligonucleotides 
mimicking these mutations were manufactured and subjected to electrophoretic mobility shift 
assay (EMSA) analysis. With WT DNA, ZBED6 bound as expected, indicated by a shift in the 
protein and DNA bands. However, ZBED6 was unable to bind to either the C+, G>A, or 
A>G/G>A oligonucleotide (data not shown). In agreement with previous studies, the G>A 
substitution was successful at inhibiting ZBED6 binding (Van Laere et. al, 2003). The C-
insertion mutation was equally effective at preventing ZBED6 binding. Given the inability of 
ZBED6 to bind, these mutations would be expected to result in increased IGF2 expression 
postnatally under conditions where ZBED6 would normally repress IGF2 expression. However, 
because ZBED6 cannot bind methylated sites, IGF2 expression in tissues in which the ZBED6 
binding site is typically methylated may not be affected by the mutation. For example, in the pig, 
the ZBED6 binding site in liver is typically methylated, therefore the G>A mutation does not 
alter gene expression of IGF2 in the liver and circulating IGF2 (Van Laere et al., 2003).  
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Body weight and composition  
Offspring were able to inherit all mutated alleles, however, due to low breeding rates, 
only offspring from with C+ and A>G/G>A alleles were used to determine the effect of 
mutations on phenotype. As expected, body weight increased with increasing age (P<0.01). At 
21d and 35d of age, body weight did not differ between genotypes (P≥0.21). At 49d of age body 
weight was different between genotypes (P=0.05) with C+ mice being 13% heavier (P=0.02) 
than WT mice, and A>G/G>A being intermediate and not different (P=0.52) from C+ mice but 
tended to be different from (P=0.07) WT mice (Figure 2.4). At 63d and 77d mice carrying either 
mutation were 10-13 % heavier (P≤0.03) than their WT counterparts.  
Mice gained more lean mass with increasing age (P<0.01). Mutated mice tended to 
acquire lean mass at a faster rate than their WT counterparts (interaction P=0.08) (Figure 2.5).  
Lean mass did not differ between genotypes at 21d and 35d. However at 49d, lean mass tended 
to be different between genotypes (P=0.06), with C+ mice having 13% more (P=0.03) lean mass 
than WT mice, with A>G/G>A being intermediate and not different (P≥0.15) from both 
extremes. At 63d, lean mass tended to be different between genotypes (P=0.07), in which C+ and 
A>G/G>A mice had 10.02% greater lean mass than WT mice. At 77d, lean mass was different 
between genotypes (P=0.02) in which C+ mice had 12% greater (P<0.01) lean mass than WT 
mice with A>G/G>A mice being intermediate and not different (P=0.36) from C+ mice but 
tended to be greater (P=0.052) than WT mice. However, when normalized to body weight, lean 
mass as a percentage of body weight was not different between genotypes (P≥0.12). 
As mice aged, they acquired more fat mass (P<0.01), and an interaction between 
genotype and age for fat mass was observed with mutated mice gaining fat mass at a faster rate 
than WT mice (P=0.04). There were no differences in fat between genotypes at 21d or 35d 
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(P³0.57). On 49d A>G/G>A mutant mice had 36% more fat (P=0.01) than WT and C+ mice, 
however, at 63d and 77d both mutations had 17-20% greater fat mass (P≤0.05) than WT mice. 
When normalized to body weight, there were no differences (P≥0.24) in fat between genotypes, 
with the exception of 49d where A>G/G>A had 28% greater fat (P=0.02) than C+ and WT mice.  
Carcass weights were also not different between genotypes at 21d of age (P=0.83), but 
were increased in IGF2 mutated mice at 49d with A>G/G>A and C+ mice being 15-17% heavier 
than WT mice (P=0.03) (Figure 2.6). At 77d of age, carcass weight tended to be different 
between genotypes (P=0.07) with A>G/G>A mutated mice being 11% greater than WT 
(P=0.04), C+ being intermediate and not different from WT mice (P=0.75) but had a tendency to 
be different (P=0.07) from A>G/G>A. It was expected that carcass weight would reflect the 
longitudinal differences in body weight with mutated mice being heavier than WT mice at 77d, 
however, C+ mice were not different from WT or A>G/G>A. Given that carcass weight is 
determined after the removal of the skin, viscera, head, feet, and tail, the remaining differences in 
carcass weight between genotypes is due to muscle, bone, and fat.  
Organ, Fat, and Muscle Weights  
To determine the components that contributed to increased body weight in mice with 
mutant IGF2 alleles, 8 mice of each genotype were sacrificed at 21, 49 and 77d of age and 
subjected to dissection. This allowed the weight of various components—muscle, adipose tissue, 
organs—to be compared. There were no differences in liver weight between genotypes at 21d 
and 49d (P≤0.26) (Figure 2.7). However, liver weight at 77d tended to be increased (P=0.07) by 
29% in C+ mice compared with A>G/G>A (P=0.04) and with WT mice being intermediate and 
similar (P≥0.21) to both extremes. When expressed as a percentage of body weight, liver weight 
did not differ (P≥0.11) between genotypes at any age.  
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There were no differences in heart weight between genotypes at 21d and 77d (P≥0.39), 
however, however, heart weight at 49 days was different between genotypes (P=0.01). Heart 
weight was increased by 12.31% (P<0.01) in C+ compared to WT mice at 49d of age with 
A>G/G>A mice being intermediate and not different from WT mice (P=0.16) but tended to be 
different from C+ mice (P=0.07). Taken as a percentage of body weight, mice tended to be 
different between genotypes (P=0.08) with genotype A>G/G>A having 17% lighter hearts than 
WT (P=0.05) and C+ mice were intermediate and similar to WT mice (P=0.86) but tended to be 
different from A>G/G>A mice (P=0.07) at 21d. At 49d, hearts normalized to body weight tended 
to be different between genotypes (P=0.08) with C+ mice having 12% heavier hearts than 
A>G/G>A (P=0.03) and WT mice were intermediate and not different between the two 
genotypes (P≥0.18). At 77d of age, there were no differences in heart weight as a percentage of 
body weight between genotypes (P=0.50). 
Biceps femoris weight was not different between genotypes at 21d (Table 2.6) and 49d. 
At 77d, BF weights tended to be different (P=0.10), with A>G/G>A tending to have 25% greater 
BF (P≤0.07) than C+ and WT mice who were not different from another (P= 0.91). When 
normalized to ELW there were no differences in BF weight between genotypes at any age 
(P≤0.11). Gastrocnemius weights were not different between genotypes at any age on an 
absolute basis or as a percentage ELW (P≥0.11). Absolute weight of the TB was not different 
between genotypes (P≥0.15) at any age. At 21d when normalized to body weight, mice tended to 
have different TB (P=0.09), where A>G/G>A mice tended to have 33% greater TB (P≥0.10) 
than C+ and WT mice who were not different from one another (P=0.61). However, there were 
no differences between genotypes at 49d and 77d (P≥0.12) in TB as a percentage ELW.  
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The absolute weight of the TA tended (P=0.09) to be different between genotypes at 21d, 
with a 33% increase in A>G/G>A mice compared to C+ mice (P=0.5), and WT mice were 
intermediate and tended to be different from C+ mice, but was not different to A>G/G>A mice 
(P=0.84). At 49d there were no differences in TA weight between genotypes (P=0.34), but at 
77d mutated mice had greater TA 20% greater TAs that WT mice (P=0.03). As a percentage 
ELW, A>G/G>A and WT mice were 33% heavier than C+ mice (P=0.02) at 21d. At 49d, as a 
percentage ELW, the TA tended to be 16% greater (P=0.09) in A>G/G>A and WT mice than C+ 
mice, but at 77d both mutations tended to have 33% greater TA as a percentage ELW compared 
to WT mice (P=0.08).  
Given that live animal data obtained through ECHO MRI indicated an increase in 
absolute fat accumulation in A>G/G>A and C+ mice, it was expected that dissection weights of 
the fat depots would be increased in mutated mice as well. No differences were observed in fat 
mass taken as absolute weight or as a percentage of ending live weight in any of the fat depots 
dissected (P≥0.12) (Table 2.7), with the exception of SF as a percentage of ELW at 49d. There 
was a trending difference (P=0.07) in SF as a percentage ELW at 49d with A>G/G>A and WT 
having 56% more SF than C+ mice. Therefore, the lack of differences between genotypes was 
inconsistent with the MRI estimations.  
Liver IGF2 Expression 
 Given the increase in body weight, liver weight, heart weight and muscle weight, it is 
more likely these mutations in mice led to a global increase in IGF2 expression and not a 
muscle-specific increase as observed in pigs. Therefore, we quantified hepatic IGF2 expression 
at 21, 49, and 77d of age. Previous reports have documented reduced hepatic expression of IGF2 
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with increasing age in pigs (Lui et al, 2008). This was evident in these mice, as well. Expression 
of IGF2 decreased with age (P=0.02) (Figure 2.8) with no interaction between genotype and age 
(P=0.27). IGF2 expression was greatly increased in mutated mice compared to WT mice at every 
age. At 21d, IGF2 expression was increased by at least 32-fold in mutated mice compared with 
their wild type counterparts (P≤0.01), at 35d IGF2 expression was increased by at least 27 fold 
(P=0.01), and at 77d expression was increased by at least 12 fold in mutated mice compared to 
wild types. At all ages, IGF2 expression was not different between C+ and A>G/G>A mice 
(P≥0.55).  
Serum IGF2 protein quantification  
Liver is the primary source of circulating IGF2. Therefore, increased hepatic IGF2 
expression would be expected to increase circulating IGF2 (Figure 2.8). However, IGF2 protein 
in serum were not different in mutated mice (P=0.16). Contrary to our hypothesis, while not 
statistically significant, there was a 7% reduction in serum IGF2 protein C+ mice and a 15% 
reduction in A>G/G>A mice compared with WT mice. Therefore, increased circulating IGF2 
protein does not appear to the mechanism by which growth is increased in IGF2 mutant mice.  
Muscle Fiber Size and Number 
 To determine if mutating the ZBED6 binding site altered muscle growth, muscle fiber 
number and cross sectional area was analyzed through histology of the TA from 77d mice 
(Figure 2.9). Average fiber area within the TA was not different between genotypes (P=0.64) 
(Figure 2.10). Muscle fiber number was not different between genotypes (P=0.92). Due to 
increased muscle mass observed in pigs with the A paternal allele, it was expected that the mice 
would have increased muscle growth due to either an increase in hyperplasia or hypertrophy of 
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the muscle fibers. However, there were no differences in muscle fiber CSA and muscle fiber 
number between genotypes.   
Discussion 
 
Body weight and composition analyses suggest that mutated mice are heavier than WT 
mice without altered composition. This was unexpected as at the same body weight pigs carrying 
the paternal A allele had a 4-5% increase in loin eye area (Jeon et al., 1999; Van den 
Maagdenberg et al., 2008), with a 7-21% reduction in back fat thickness (Jeon et al., 1999; 
Jungerius et al., 2004; Gardan et al., 2006; Van den Maagdenberg et al., 2008; Burgos et al., 
2011). While mice with mutations disrupting the ZBED6 binding site did have differences in 
lean and fat accumulation, these differences were not observed when normalized to body weight, 
unlike the pigs. Similar to these data, other mutations in mice that resulted in increased IGF2 
expression, as in the IGF2R knockout mice, were observed to have increased body weights 
140.0% of WT weight at birth, however, these mutations were perinatally lethal (Ludwig et al., 
1996). A limitation of these data is that these animals were subjected to ECHO MRI within a 
range of ± 3 days so that each collection time point contained animals that were potentially 6 
days apart. Additionally, this could result in as little as 5 days difference in between sampling 
time points. This may have introduced additional variation within the data and obscured true 
effects. In the future, studies should better control for age to limit this potential variation.  
One possible explanation for increased body weight without apparent increases in muscle 
or adipose tissue weight is an increase in bone mass. As IGF are the most abundant growth 
factors produced and stored by bone (Mohan et al, 1991, 1994), systemically increasing their 
expression may have growth-enhancing effects. Similar to muscle, IGF2 is expressed at lower 
levels than IGF1 in bone postnatally in mice and rats (Mohan et al, 1991, 1994). Exogenous 
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expression of IGF2 enhanced bone morphogenetic protein-9 induced endochondral ossification, 
and IGF2 itself promoted the expansion of the hypertrophic chondrocyte zone in cultured limb 
explants (Chen et al., 2010). Therefore, it is possible that mutations disrupting ZBED6 binding 
caused increased bone IGF2 expression and therefore, increased bone growth. It is possible that 
the ZBED6 binding site in bone is unmethylated in mice but is methylated in pig, however, these 
data are currently unknown.  
Given that live animal data obtained through ECHO MRI indicated an increase in 
absolute fat accumulation in A>G/G>A and C+ mice, it was expected that dissection weights of 
the fat depots would be increased in mutated mice as well. Therefore, the lack of differences 
between genotypes was inconsistent with the MRI estimations. As ECHO MRI estimation of fat 
was not significantly different from chemical analysis of fat in a validation study (Jones, 
Johnson, and Nagy, 2009), fat mass according to ECHO MRI in this study is more effective than 
dissection data. These results were also inconsistent with that of the pig. In pigs with paternal A 
alleles, a decrease in subcutaneous fat mass was observed (Jeon et al, 1999; Nezer et al, 2003; 
Van Laere et al, 2003;), while mutated mice did not have an increase in fat. It is possible that 
there is a difference in nutrient partitioning between mice and pigs. Because tissue growth is 
allometric, with bone reaching its growth plateau first, followed by muscle then fat, increasing 
the growth plateau of muscle may decrease the deposition of fat (Jones 2014).  The increase in 
skeletal muscle in pigs due to the mutation may decrease the nutrient availability for adipose 
because muscle has a higher priority for nutrients (Aberle et al., 2001), and therefore a reduction 
in back fat is observed. Other species in which mutations cause increased muscle growth, such as 
the myostatin knockout mutation in cattle, were also observed to have a decrease in adipose 
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tissue deposition (Shahin et al., 1985). Because mice appear to have an overall increase in body 
size without muscle specific growth, fat accumulation is not altered. 
While the G>A mutation within the ZBED6 binding of site of pigs increased muscle 
mass and decreased subcutaneous fat without altering body weight (Clark et. al., 2015), the effect 
of such a mutation in other species was unknown. Given the increase in skeletal muscle IGF2 
expression and the established phenotypes of pigs, it was hypothesized that mice with these 
mutations would have increased muscle mass and decreased fat deposition with similar body 
weights. However, mutated mice were heavier than their WT counterparts at the same age. 
Contributing to this increase in body weight, live animal measurements taken with ECHO MRI 
indicate that mutated mice have greater absolute lean and fat accretion. However, this was not 
observed in muscle and fat pads, and when taken as a percentage of body weight, there are no 
differences in lean or fat between genotypes. This suggests that body composition was not 
affected by mutating the ZBED6 binding site of IGF2 in mice. However, body composition data 
were not properly controlled for differences between litters.  
Due to limitations with litter sizes, only 14 out of 48 mutated mice with a mutation had a 
WT control from the same litter in their time point. At 77d, only 3 of the 11 litters had both a 
mutated mouse and a WT mouse from the same litter. At 49 days, 3 of the 11 litters had proper 
controls, and all of these three litters were again C+ mutants. At 21d, only 2 of the 10 litters had 
proper control. All of the litters that had proper control were C+ mutants, therefore, A>G/G>A 
mice never had proper controls. Therefore, without a WT mouse from the same litter as a 
mutated mouse, variation between litters cannot be accounted for properly. Due to the lack of 
proper controls in this study, the conclusions drawn from this study are limited. Future studies 
should exclude animals with mutations that do not have a wild type control from the same litter 
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so that comparisons between genotypes are not confounded by litters that may be heavier than 
others. Another limitation of these data is that tissues were not error checked at the time of 
dissection. Muscles and fat pads from both sides of the body were dissected and weighed, 
however, it was not tested to ensure that one side did not weigh significantly more than the other.  
Because it cannot be determined which side of the carcass is the most accurate, the average of 
the two muscles was used to determine the effects of genotype (Table A1). Taking the average of 
both sides would give the greatest confidence to account for imprecision in dissection technique. 
Additionally, the coefficient of variation (calculated by the standard deviation within age divided 
by the mean within age multiplied by 100) of the average was lower than the coefficient of 
variation from either side individually (Table A2). Coefficients of variation decreased with 
increasing age. Muscle and adipose weights from each side of the carcass should be error 
checked at the time of dissection in future studies to ensure that dissection error is not 
contributing to variation between each side. An early detection of the imprecision would have 
allowed for alterations in dissection technique to improve accuracy. Failure to dissect the entire 
muscle or fat depot provides an inaccurate representation of the tissue, and therefore confounds 
results. As this study did not ensure that the two sides were not within a reasonable weight from 
each other, conclusions drawn from the data are limited.    
It is not surprising that C+ mutated mice had larger hearts than WT mice, as a similar 
effect was observed in pigs carrying a paternal A allele which had increased IGF2 expression in 
the heart that translated to 5.3% larger hearts than their wildtype counterparts (Jeon et al., 1999; 
Van Leare et al., 2003). Additionally, increased levels of IGF2 due to an IGF2R knockout in 
mice caused 4-fold greater heart weights than their wildtype counterparts at embryonic day 18.5. 
This increase was mainly due to an increase in thickening of the heart wall without an increase in 
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hypertrophy and was embryonically lethal (Ludwig et al., 1996). Furthermore, no differences in 
liver weight were observed in pigs carrying an A paternal allele, which is consistent with our 
data with the exception of C+ mice having heavier livers at 77d. Mice carrying the C+ mutation 
had carcass weights that were not different between A>G/G>A and WT mice, which was 
unexpected given that it was observed with longitudinal data that both genotypes of mutated 
mice had heavier body weights than WT mice. This difference may be due to C+ mice having 
larger livers than A>G/G>A mice.   
The lack of congruency between mutant mouse and mutant pig phenotypes may be due to 
differences in the methylation patterning in mice compared with pigs. In pig skeletal muscle, the 
CpG island located in the binding site was essential unmethylated with 3.4% methylation, 
however, the liver had an average of 26% methylation (Van Laere et al., 2003). Thus, ZBED6 in 
pigs may have a greater effect in skeletal muscle than in liver due to its inability to bind 
methylated binding sites (Markljung et al., 2009).  It is possible that this difference in 
methylation patterning is due to pigs being selected for lean muscle growth, causing a decrease 
in methylation in skeletal muscle allowing for increased transcription. This lack of methylation 
in the muscle would allow for ZBED6 to bind and inhibit IGF2 expression absent a mutation in 
the IGF2 ZBED6 binding site. Thus, altering the binding site affects muscle growth in pigs. On 
the other hand, C57BL6/J mice used in this experiment have not been selected for lean muscle 
growth. Therefore, they may have hypermethylated ZBED6 binding sites in IGF2, causing 
ZBED6 binding to be unaffected by disruptions in the binding site due to mutation in muscle. In 
mice, the ZBED6 binding site in liver may be hypomethylated so that WT alleles would be able 
to interact with ZBED6 allowing IGF2 expression to be suppressed, while mutated alleles 
prevent ZBED6 binding, thus increasing expression in the liver. Therefore, an increase in 
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circulating IGF2 may cause an increase in whole body growth, as opposed to a paracrine 
response in skeletal muscle.  
It was expected that the increased hepatic expression of IGF2 would translate to 
increased circulating IGF2 protein, as hepatocyte-specific IGF-1 transgenic mice that result in 
increased hepatic IGF-1 expression without increasing expression in other tissues were shown to 
exhibit 3-fold increases in serum IGF1 (Elis et al., 2010). However, no differences in circulation 
IGF2 were observed between genotypes. Therefore, it does not appear to be the mechanism by 
which growth is increased in IGF2 mutant mice. It is possible that the increased growth observed 
in mice is due to an increase in local IGF2 acting on cells in an autocrine or paracrine method. 
However, it is important to note that the lack of differences in circulating IGF2 protein 
concentrations between genotypes may be due to the inability of the ELISA to bind to IGF2 that 
is in a complex with an IGF binding protein (IGFBP). Most IGF in the extracellular environment 
are bound to IGFBPs that function to transport, extend the half-life, regulate turnover, and help 
to prevent hypoglycemic effects by preventing cross binding of IGF to the insulin receptor 
(Rajaram, Baylink, and Mohan 1997).  Additionally, increasing IGF in circulation increases the 
expression of IGFBP (Zapf et al., 1990), therefore the increased expression of hepatic IGF2 
observed in mutated mice may also increase the expression of IGFBP. This may, in turn, cause 
the lack of difference observed between genotypes in circulating IGF2 despite the increase in 
hepatic IGF2 expression in mutated genotypes. Therefore, these preliminary data suggest that 
mutated mice have increased expression of IGF2 and likely increased circulating IGF2, though 
future studies should seek to elucidate the differences in circulating proteins through Western 
Blotting that would not be affected by binding proteins.  
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Conclusions 
Overall, these preliminary data suggest that the phenotype of mice with mutations 
disruption the ZBED6 binding site in intron 3 of IGF2 differs from that of pigs. These mutations 
did, however, increase IGF2 expression in the liver. It is possible that the ZBED6 binding site is 
hypomethylated in mouse liver, therefore, binding is altered due to the mutation, thus the 
mutation may not be effective in inducing muscle specific growth but rather an increase in whole 
body growth. The increased body weight in mutated mice indicates that IGF2 may play a larger 
role in postnatal growth than previously thought. However, due to a lack of proper control 
animals used in this study, these conclusions are limited.   
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Tables 
 
Table 2.1 Transcription activator-like effector nucleases target sites 
Left Binding site  
(5' - 3' on +ve strand) Spacer 
Right Binding site  
(5' - 3' on +ve strand) 
TGCCTGGCCCCGACTTCG CCTAGGCTCGCGGCGT CTGAGCGCGTGGGGCGCA 
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Table 2.2 Oligodeoxynucleotide sequence for co-injection with TALEN1 
Wild type 
AACTGAGCTAGGGACGAGTCTGCCCCCGGCGGCTGCCTGGCCCCGACTTCGCCT
AGGCTCGCGGCGTCTGAGCGCGTGGGGCGCAGGGGCGGCGGGGAGCCGAGCGG
GGCGCCGGAACCTA 
Oligo 
AACTGAGCTAGGGACGAGTCTGCCCCCGGCGGCTGCCTGGCCCCGGCTTCGCCT
AGGCTCACGGCGTCTGAGCGCGTGGGGCGCGGGGGCGGCGGGGAGCCGAGCGG
GGCGCCGGAACCTA 
1Locations of designed mutations are underlined. The ZBED6 binding site is highlighted in grey.  
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Table 2.3 Primer sequence for genotyping IGF2 mutant mice 
Primer Sequence 
Forward (IGF2) TTCTAGCATCCGGCAACGGT 
Reverse (IGF2) TTCGCCTTCTAGCCAACGAG 
	
	
54	
  
Table 2.4 Oligodeoxynucleotide sequences for EMSA 
Oligo Name Sequence (5' to 3') 
Wild Type Forward CGACTTCGCCTAGGCTCGCGGCGTCT 
Wild Type Reverse AGACGCCGCGAGCCTAGGCGAAGTCG 
G>A Forward CGACTTCGCCTAGGCTCACGGCGTCT 
G>A Reverse AGACGCCGTGAGCCTAGGCGAAGTCG 
A>G/G>A Forward CGGCTTCGCCTAGGCTCACGGCGTCT 
A>G/G>A Reverse AGACGCCGTGAGCCTAGGCGAAGCCG 
C+ Forward CGACTTCGCCTAGGCCTCGCGGCGTCT 
C+ Reverse  AGACGCCGCGAGGCCTAGGCGAAGTCG 
	
	
55	
Table 2.5 Quantitative PCR gene names and assay identification numbers 
Gene Symbol Gene Name Accession Number Assay ID1 Reporter 
IGF2 Insulin-like growth factor 2  NM_001122736.1 Mm00439564_m1 FAM 
18s RNA Eukaryotic 18S rRNA NR_003278.3 4319413E VIC 
Actin Actin, Beta NM_007393.1 4352341E VIC 
1All primers are Taqman primers purchased from Thermo Fisher Scientific Inc; Waltham, MA 
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Table 2.6 Effects of mutation in the ZBED6 binding site of IGF2 in mice on muscle 
weights at 21 days of age 
   Strain   
    A>G/G>A  C+ WT SEM P-Value 
21d of age, mice 8 8 8   
Biceps femoris, mg 48.18 48.76 47.74 6.37 0.99 
Biceps femoris, % ELW 0.46 0.46 0.45 0.05 0.98 
Triceps brachii, mg 35.41 29.96 33.83 2.91 0.41 
Triceps brachii, % ELW 0.04 0.03 0.03 0.02 0.09 
Gastrocnemius, mg 33.34 37.70 37.49 3.66 0.64 
Gastrocnemius, % ELW 0.32 0.35 0.36 0.01 0.11 
Tibialis anterior, mg 25.41 19.09 24.79 2.14 0.09 
Tibialis anterior, % ELW 0.24a 0.18b 0.24a 0.01 0.02 
49d of age, mice 8 8 7   
Biceps femoris, mg 210.10 186.90 163.10 17.45 0.17 
Biceps femoris, % ELW 0.85 0.73 0.77 0.06 0.33 
Triceps brachii, mg 96.37 89.61 85.67 5.79 0.41 
Triceps brachii, % ELW 0.10 0.09 0.09 0.02 0.12 
Gastrocnemius, mg 126.40 121.40 121.40 7.75 0.14 
Gastrocnemius, % ELW 0.51 0.48 0.50 0.03 0.58 
Tibialis anterior, mg 69.58 61.59 60.93 4.76 0.34 
Tibialis anterior, % ELW 0.28 0.24 0.29 0.02 0.09 
77d of age, mice  8 8 8   
Biceps femoris, mg 237.60 189.80 192.50 16.86 0.10 
Biceps femoris, % ELW 0.84 0.66 0.75 0.06 0.11 
Triceps brachii, mg 115.80 118.30 100.20 6.81 0.15 
Triceps brachii, % ELW 0.12 0.12 0.10 0.02 0.70 
Gastrocnemius, mg 140.90 149.20 142.80 8.29 0.76 
Gastrocnemius, % ELW 0.49 0.52 0.55 0.02 0.16 
Tibialis anterior, mg 82.30a 84.78a 61.46b 6.21 0.03 
Tibialis anterior, % ELW 0.29 0.29 0.24 0.02 0.08 
1Maximum standard error of the mean. 
2Muscle weight as a percentage of Ending Live Weight (ELW)= (Weight/ELW) *100 
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Table 2.7 Effects of mutation in the ZBED6 binding site of IGF2 in mice on fat depot 
weights at 21 days of age 
  Strain   
				 A>G/G>A  C+ WT SEM P-Value 
21d of age, mice 8 6-83 7-84   
Inguinal Fat, mg 38.74 37.29 49.95 6.29 0.32 
Inguinal Fat, % ELW 0.37 0.34 0.48 0.05 0.12 
Subscapular Fat, mg 40.39 36.77 36.71 8.62 0.94 
Subscapular Fat, % ELW 0.39 0.35 0.33 0.07 0.86 
Epididymal Fat, mg 12.78 14.29 21.38 3.96 0.28 
Epididymal Fat, % ELW 0.12 0.12 0.19 0.03 0.15 
Retroperitoneal Fat, mg 2.29 2.05 1.51 0.48 0.45 
Retroperitoneal Fat, % ELW 0.02 0.02 0.02 0.01 0.67 
49d of age, mice 8 8 7   
Inguinal Fat, mg 78.94 75.66 67.87 5.67 0.37 
Inguinal Fat, % ELW 0.32 0.30 0.32 0.02 0.59 
Subscapular Fat, mg 55.22 35.83 43.53 6.84 0.12 
Subscapular Fat, % ELW 0.22 0.14 0.21 0.03 0.07 
Epididymal Fat, mg 90.56 73.88 69.11 8.93 0.20 
Epididymal Fat, % ELW 0.37 0.29 0.33 0.04 0.28 
Retroperitoneal Fat, mg 17.64 15.57 12.69 2.23 0.29 
Retroperitoneal Fat, % ELW 0.07 0.06 0.06 0.01 0.59 
77d of age, mice  7-85 8 7-86   
Inguinal Fat, mg 79.39 74.44 71.24 9.58 0.82 
Inguinal Fat, % ELW 0.28 0.26 0.28 0.04 0.92 
Subscapular Fat, mg 41.42 35.90 37.78 5.76 0.79 
Subscapular Fat, % ELW 0.14 0.12 0.15 0.02 0.68 
Epididymal Fat, mg 91.97 119.20 77.56 14.10 0.13 
Epididymal Fat, % ELW 0.33 0.41 0.30 0.05 0.34 
Retroperitoneal Fat, mg 21.06 15.53 18.32 2.63 0.33 
Retroperitoneal Fat, % ELW 0.07 0.05 0.07 0.01 0.23 
1Maximum standard error of the mean. 
2Fat weight as a percentage of Ending Live Weight (ELW)= (Weight/ELW)*100 
3Retroperitioneal Fat (RF), and RF as a percentage of ELW n=6 
4Retroperitioneal Fat (RF), and RF as a percentage of ELW n=7 
5Retroperitioneal Fat (RF), and RF as a percentage of ELW n=7 
6 Inguinal Fat (IF), IF as a percentage of ELW, Subscapular Fat as a percentage of ELW, and 
Epididymal Fat as a percentage of ELW n=7 
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Figures 
 
Figure 2.1 Methylation statuses of CpG islands in IGF2 
 
 
 
Methylation status of CpG sites surrounding the target IGF2 14195 locus in mouse embryonic 
stem cells. Each row is a sequenced DNA strand with the white circles representing 
unmethylated CpG islands, and the black circles representing methylated CpG islands. The target 
site for mutation is at CpG island location 74. The binding sites for the TALEN include CpG 
islands 29-127.   
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Figure 2.2 Band results of restriction fragment length polymorphism for each genotype using 
(A) StuI or (B) Cac8I. A) The C+ mutant allele digested with StuI resulted in band sizes of 271 
bp and 172 bp, while the wild type alleles would not be digested giving a band size of 443bp. B) 
The G>A mutation, the mutated allele digested with Cac8I resulted in bands of 335 and 87 bp 
while wild type allele had band sizes of 237, 87, and 82 bp.
B A
C 
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WT      CTGGCCCCGACTTCGCCTAGGCTCGCGGCGTCTGAGCGCGTGGGGCGCAGGGG 
F1(♂)   CTGGCCCCGACTTCGCCTAGGCTCGCGGCGTCTGAGCGCGTGGGGCGCAGGGG WT 
           CTGGCCCCGACTTCGCCTAGGCTCACGGCGTCTGAGCGCGTGGGGCGCAGGGG    (G>A) 
(One point mutation G→A) 
 
WT      CTGGCCCCGACTTCGCCTAGGCTCGCGGCGTCTGAGCGCGTGGGGCGCAGGGG 
F1(♂CTGGCCCCGACTTCGCCTAGGCCTCGCGGCGTCTGAGCGCGTGGGGCGCAGGGG   (C+) 
 CTGGCCCCGGCTTCGCCTAGGCTCACGGCGTCTGAGCGCGTGGGGCGCAGGGG   (A>G/G>A) 
(Two point mutations, A →G and G→A) 
 
 
Figure 2.3 Founder mice DNA sequences compared to wild type mice. Target sites for the mutations are bold, with mutated 
nucleotides underlined twice, and designed mutations underlined once.  
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Figure 2.4 Body weight of C+, A>G/G>A, and wild type mice at 21, 35, 49, 63, 77 days of age. 
Least square means are reported ± standard error of the mean. * designates significant difference 
between WT and mutant genotypes P< 0.05. 
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Figure 2.5 Body composition traits for (A) Lean mass (B) Lean mass as a percentage of body weight (C) Fat mass (D) Fat mass as a 
percentage of body weight are displayed. Least square means are reported ± standard error of the mean. Means without a common 
letter are different (P< 0.05).  Lower case letters represent differences within age group, upper case letter indicates differences over 
ages.
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Figure 2.6 Carcass weight of C+, A>G/G>A, and wild type mice at 21, 49, 77 days of age. Least 
square means are reported ± standard error of the mean. Means without a common letter are 
different (P< 0.05). 
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Figure 2.7 A) Heart weight B) Heart weight as a percentage of Ending Live Weight (ELW) C) Liver weight D) Liver as a percentage 
of ELW. Least square means are reported ± standard error of the mean. Means without a common letter within an age are different 
(P< 0.05). 
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Figure 2.8 A) Insulin-like growth factor 2 expression in the liver at age 21, 49 and 77 days for wild type, C+, and A>G/G>A mice. B) 
IGF2 Protein levels in serum of 77 day old mice. IGF2 levels were determined in duplicate by an ELISA kit with a sensitivity of 
<5pg/ml. The ELISA had no cross-reactivity with IGF-1. Least square means are reported as means ± standard error of the mean. 
Lower case letters represent differences within age group, upper case letter indicates differences over ages. Means without a common 
letter are different (P< 0.05). 
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Figure 2.9 Representative images of cross section of H&E analysis from the tibialis anterior of (A) A>G/G>A mutant mice, (B) C+ 
mice mutations and (C) wild type mice.
A B 
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Figure 2.10 Muscle fiber number (A) and muscle fiber cross sectional area (B) from the tibialis anterior muscle of 77 day old mice. 
Least square means are reported as means ± standard error of the mean.
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Appendix A 
 
 
 
  
Table A1 P-values representing differences in genotypes for muscle and fat pad weights from each side of 
the carcass and the average of the two at 21, 49, and 77 days of age 
Age (d) 
Muscle/ 
Fat Pad Right Left  Average  Age (d) 
Muscle/ 
Fat Pad as 
% ELW Right Left  Average 
21 BF 0.704 0.478 0.994  21 BF 0.622 0.540 0.982 
21 TA 0.155 0.151 0.094  21 TA 0.137 0.008 0.016 
21 TB 0.508 0.465 0.410  21 TB 0.097 0.259 0.090 
21 G 0.884 0.449 0.644  21 G 0.653 0.079 0.105 
21 IF 0.315 0.344 0.317  21 IF 0.129 0.358 0.118 
21 EF 0.433 0.211 0.282  21 EF 0.267 0.121 0.152 
21 SF 0.982 0.846 0.942  21 SF 0.960 0.721 0.864 
21 RF 0.569 0.670 0.449  21 RF 0.770 0.677 0.666 
           
49 BF 0.040 0.578 0.171  49 BF 0.061 0.941 0.327 
49 TA 0.559 0.164 0.340  49 TA 0.648 0.023 0.087 
49 TB 0.518 0.406 0.406  49 TB 0.218 0.200 0.125 
49 G 0.154 0.172 0.144  49 G 0.605 0.606 0.577 
49 IF 0.075 0.474 0.366  49 IF 0.124 0.631 0.588 
49 EF 0.545 0.132 0.200  49 EF 0.725 0.184 0.279 
49 SF 0.346 0.042 0.124  49 SF 0.281 0.022 0.073 
49 RF 0.232 0.511 0.292  49 RF 0.500 0.568 0.595 
           
77 BF 0.042 0.321 0.103  77 BF 0.071 0.145 0.111 
77 TA 0.023 0.053 0.028  77 TA 0.058 0.186 0.085 
77 TB 0.324 0.116 0.150  77 TB 0.865 0.619 0.698 
77 G 0.745 0.854 0.762  77 G 0.298 0.302 0.163 
77 IF 0.710 0.752 0.822  77 IF 0.571 0.932 0.922 
77 EF 0.127 0.243 0.131  77 EF 0.289 0.527 0.338 
77 SF 0.973 0.488 0.791  77 SF 0.894 0.353 0.675 
77 RF 0.420 0.409 0.326   77 RF 0.443 0.272 0.225 
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Table A2 Coefficients of variation for muscle and fat pad weights 
pooled across all three genotypes from each side of the carcass and 
the average of the two at 21, 49, and 77 days of age 
Age (d) Muscle/ Fat Pad Right   Left Average1 
21 Biceps femoris 44.75  38.46 35.69 
21 Triceps brachii 26.99  28.13 24.78 
21 Gastrocnemius 26.99  32.40 27.93 
21 Tibialis anterior 31.76  30.97 28.03 
21 Inguinal Fat 43.67  43.20 42.76 
21 Subscapular Fat 62.87  64.10 61.53 
21 Epididymal Fat 63.85  83.09 70.36 
21 Retroperitoneal Fat 64.73  92.20 59.18 
      
49 Biceps femoris 30.33  28.16 25.62 
49 Triceps brachii 19.91  16.81 16.84 
49 Gastrocnemius 17.79  19.86 18.22 
49 Tibialis anterior 23.03  22.16 19.75 
49 Inguinal Fat 25.70  22.93 20.21 
49 Subscapular Fat 47.29  42.79 42.66 
49 Epididymal Fat 40.27  34.12 31.22 
49 Retroperitoneal Fat 48.00  42.42 38.88 
      
77 Biceps femoris 30.53  24.25 24.57 
77 Triceps brachii 21.96  17.97 18.07 
77 Gastrocnemius 19.96  15.85 15.72 
77 Tibialis anterior 29.25  24.33 26.12 
77 Inguinal Fat 34.23  40.71 32.47 
77 Subscapular Fat 45.42  49.76 41.05 
77 Epididymal Fat 50.00  45.27 43.64 
77 Retroperitoneal Fat 95.61  52.92 38.52 
1The coefficient of variation after the weight of the right side and 
left side were averaged 
